Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 9/20 | 0.53 |
| ▸ | KIF5B | P33176 | 5/20 | 0.53 |
| ▸ | EGFR | P00533 | 7/20 | 0.52 |
| ▸ | FLT1 | P17948 | 3/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | FBP1 | P09467 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18013043 | 0.90 | RET (0.49) | RETKIF5BEGFRFLT1KDR | |
| SCHEMBL18013029 | 0.88 | EGFR (0.69) | RETKIF5BEGFRFLT1KDR | |
| SCHEMBL19885278 | 0.88 | RET (0.52) | RETKIF5BEGFRFLT1KDR | |
| SCHEMBL18012083 | 0.82 | KCNH2 (0.63) | EGFRFLT1KDR | |
| SCHEMBL19885271 | 0.82 | KDR (0.54) | RETKIF5BEGFRFLT1KDR | |
| SCHEMBL18012882 | 0.81 | FBP1 (0.69) | EGFRKDRFBP1 | |
| SCHEMBL17967506 | 0.81 | FLT1 (0.77) | EGFRFLT1KDRFGFR1 | |
| SCHEMBL18012075 | 0.81 | FBP1 (0.72) | EGFRKDRFBP1 | |
| SCHEMBL19885264 | 0.81 | KDR (0.62) | RETKIF5BEGFRFLT1KDR | |
| SCHEMBL19885305 | 0.81 | EGFR (0.58) | RETKIF5BEGFRKDRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | RET 49/4885KIF5B 1171/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.